Looking for an edge in a competitive market, Oxford Nanopore moves into mRNA vaccine testing
Researchers at the University of Queensland say they’ve developed a faster way to put mRNA vaccines through quality control testing, according to a study published today in Nature Communications.
Oxford Nanopore, the company whose technology is integral to the process, is touting the findings as it looks for an edge in the increasingly competitive space of genetic sequencing. Companies like Oxford Nanopore and Illumina read DNA for research and diagnostic purposes, but Oxford Nanopore sees big potential in testing mRNA vaccines and therapeutics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.